News, trade fairs, press information
LTS announces the appointment of David Doles as new President and Chief Executive Officer for its US affiliate LTS Corp.
LTS Lohmann Therapie-Systeme AG, the market leader for the development and manufacturing of transdermal therapeutic systems, is very pleased to announce the appointment of Mr. David Doles as the President and Chief Executive Officer for its US affiliate, LTS Lohmann Therapy Systems, Corp. effective 1 January 2020.
European patent granted for LTS’ asenapine TTS
LTS is pleased to announce that the European Patent Office has issued their decision to grant an European Patent (EP 3338768 B1) for LTS’ application relating to an asenapine transdermal therapeutic system (TTS). The asenapine TTS is a twice-weekly transdermal patch for the treatment of schizophrenia and is one of LTS’ proprietary projects. The LTS [...]
Meet us at the CPHI worldwide in Frankfurt
Meet the LTS-Team at CPhI Worldwide 2019 from 5 - 7 November in Frankfurt at our booth 121A70.
New TTS webinar
Our new webinar "Transdermal Therapeutic Systems - Still an attractive technology?!"
German health authorities grant LTS the manufacturer’s authorisation for capsules
Inspection successfully concluded. In September, the German health authorities extended the manufacturer’s authorisation for LTS Lohmann Therapie-Systeme AG (LTS) to include capsules.